Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
NCT00349557
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
bevacizumab, bicalutamide and goserelin
PROCEDURE:
intensity modulated radiation therapy (IMRT)
Sponsor
Benaroya Research Institute
Collaborators
[object Object]